source
- Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trialTyra Biosciences announced that its experimental therapy for low‑risk bladder cancer has produced encouraging results in a Phase 2 study. The company said the data, released on Wednesday, represen…
- ARPA-H selects UpDoc, Tempus AI and Atman Health for new AI heart-disease programARPA-H announced a new initiative called ADVOCATE that will bring together three companies to develop AI-driven tools for managing heart disease. The selected firms - UpDoc, Tempus AI, and Atman H…